Received Apr 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Bell's palsy; This serious case was reported by a consumer via call center representative and described the occurrence of bell's palsy in a male patient who received Herpes zoster (Shingrix) for prophylaxis. In FEB-2025, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced bell's palsy (Verbatim: Bell's palsy) (serious criteria GSK medically significant). The outcome of the bell's palsy was unknown. It was unknown if the reporter considered the bell's palsy to be related to Shingrix. The company considered the bell's palsy to be unrelated to Shingrix. Additional Information: GSK receipt date: 25-APR-2025 The patient is the reporter. The patient received the first dose of Shingrix about 2.5 months ago in February 2025, and developed Bell's Palsy. This is 1 of the 2 cases reported by the same reporter.; Sender's Comments: Bell's palsy is an unlisted event which is considered unrelated to GSK vaccine Shingrix. US-GSK-US2025050413:Different patient